Welcome to our dedicated page for Aptevo Therapeutics SEC filings (Ticker: APVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Aptevo Therapeutics鈥� dense biotech disclosures can feel like reading a second language. Clinical-stage companies such as Aptevo juggle milestone payments, patent filings, and trial data across dozens of forms, so spotting cash-runway updates or understanding toxicology results is challenging. Stock Titan translates every Aptevo Therapeutics SEC filing into plain English, turning 300-page documents into concise briefs backed by AI-powered summaries and real-time alerts.
Whether you need the Aptevo Therapeutics quarterly earnings report 10-Q filing or want Aptevo Therapeutics insider trading Form 4 transactions, our platform surfaces what matters: burn rate trends, dilution risk, and executive stock incentives. Proprietary algorithms flag each Aptevo Therapeutics 8-K material events explained in minutes, while interactive tables track Aptevo Therapeutics executive stock transactions Form 4 as they appear on EDGAR. If you are comparing trial milestones, the Aptevo Therapeutics annual report 10-K simplified section highlights pipeline progress, key risk factors, and intellectual-property status.
Investors typically ask how to read Aptevo Therapeutics鈥� proxy statement executive compensation or where to find Aptevo Therapeutics earnings report filing analysis. Here鈥檚 the streamlined path:
- Instant notice of Aptevo Therapeutics Form 4 insider transactions real-time
- Side-by-side redline of sequential 10-Q footnotes for faster trend analysis
- Natural-language answers for understanding Aptevo Therapeutics SEC documents with AI
Stop skimming PDFs. Our AI technology extracts segment data, clinical updates, and forward-looking statements so you can focus on decisions, not document searches. Aptevo Therapeutics SEC filings explained simply鈥攁lways current, always in context.
Schedule 13G filing for Aptevo Therapeutics Inc. (NASDAQ: APVO) discloses that a group of affiliated Yorkville entities, led by YA II PN, Ltd., now beneficially owns 357,842 common shares, equal to 9.99 % of the outstanding stock. The position consists entirely of shares that the investors have the right to acquire pursuant to a $25 million Standby Equity Purchase Agreement (SEPA) executed on 16 June 2025. The SEPA prohibits Aptevo from issuing additional shares to the group if doing so would push their aggregate ownership above the 9.99 % threshold.
- Voting/Dispositive power: 0 shares sole; 357,842 shares shared.
- Outstanding shares basis: 3,224,156 shares reported by the issuer on 20 June 2025 plus the 357,842 acquisition rights held by YA II.
- Reporting persons: YA II PN, YA Global Investments II (U.S.), Yorkville Advisors Global LP, related GPs, Mark Angelo, and SC-Sigma Global Partners.
FAQ
What is the current stock price of Aptevo Therapeutics (APVO)?
What is the market cap of Aptevo Therapeutics (APVO)?
